Decision Resources: Victoza may outpace Byetta
BURLINGTON, Mass. — Novo Nordisk could be outpacing Eli Lilly and Amylin Pharmaceuticals in the diabetes wars, according to an analysis by healthcare market research firm Decision Resources.
A recent report by the firm found that more patients were switching from Lilly and Amylin’s Byetta (exenatide) to Novo Nordisk’s Victoza (liraglutide) than vice versa, with 25.2% switching to Victoza and 2.8% switching to Byetta. Still, for the time being, Byetta commands a higher patient share. Between the first and last quarters of 2010, Byetta’s patient share fell from 4% to 3.2%, while Victoza’s increase from 0.1% to 1.8%.
“Use of both Byetta and Victoza is usually reserved for later lines of therapy,” Decision Resources analyst Kate Sullivan said. “The increasing use of Victoza is most likely a result of Victoza’s more convenient once-daily dosing and its greater HbA1c-lowering and weight-loss efficacy.”
It seems oddly coincidental (perhaps manipulative) that Decision Resources would announce this research finding about Victoza on a day when Amylin stock is rising with the news of their positive heart rhythm study. Novo Nordisk has a great product, but once a day is not as convenient as once per week, and there is NO way that can be spinned other than for what it is. For once, I wish the market would stop worrying about investors and demonstrate some genuine concern about patients. The market is large and getting larger, certainly enough room for many players besides Novo, and both Amylin and Mannkind will demonstrate this convincingly in the months and years ahead.
Rate of obesity continues to rise in United States
WASHINGTON — The rate of obesity among adults has increased across 16 states, with no states seeing a drop, according to a new report released by the Trust for America’s Health and the Robert Wood Johnson Foundation.
The report also found that 12 states now have obesity rates above 30%, versus four years ago when just one state had a 30% obesity rate, TFAH and RWJF said.
Mississippi this year took the top spot as the most obese state, with Colorado falling in last place. What’s more, obesity rates have grown fastest in Oklahoma, Alabama and Tennessee, and slowest in Washington, D.C., Colorado and Connecticut.
Since 1995, when data was available for every state, obesity rates have doubled in seven states and increased by at least 90% in 10 others, TFAH and RWJF noted, adding that racial and ethnic minority adults, as well as those who are less educated and make less money, continue to garner the highest overall obesity rates.
“Today, the state with the lowest obesity rate would have had the highest rate in 1995,” TFAH executive director Jeff Levi said. “There was a clear tipping point in our national weight gain over the last 20 years, and we can’t afford to ignore the impact obesity has on our health and corresponding healthcare spending.”
No comments found
Bill Cook joins BioPlus as VP sales
ALTAMONTE SPRINGS, Fla. — BioPlus Specialty Pharmacy has named Bill Cook VP sales, the company said.
Cook previously worked as SVP business development and sales at CareSouth and also has worked as VP sales at United Therapeutics, Accredo Health and Gentiva. In his new position with BioPlus, Cook will be responsible for the national sales force.
“Bill brings over 23 years of healthcare industry experience as a dynamic, high-performance sales executive to his new position at BioPlus,” BioPlus president and CEO Stephen Vogt said. “His extensive experience in building and leading top-flight sales teams, strategic planning, incentive compensation design and market positioning is the perfect match for BioPlus as our company continues to grow and expand in the specialty pharmacy industry.”
No comments found